Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261876 | 0.90 | ACHE (0.59) | ACHEALDH1A1EPHX1L3MBTL3L3MBTL1 | |
| SCHEMBL25945885 | 0.90 | ACHE (0.59) | ACHEALDH1A1EPHX1L3MBTL3L3MBTL1 | |
| SCHEMBL20233114 | 0.90 | ACHE (0.59) | ACHEALDH1A1EPHX1L3MBTL3L3MBTL1 | |
| SCHEMBL7320518 | 0.89 | ACHE (0.66) | ACHEALDH1A1EPHX1L3MBTL3L3MBTL1 | |
| SCHEMBL22875318 | 0.88 | BLM (0.56) | ACHEALDH1A1EPHX1L3MBTL3L3MBTL1 | |
| SCHEMBL9785724 | 0.87 | ACHE (0.64) | ACHEALDH1A1EPHX1L3MBTL3L3MBTL1 | |
| SCHEMBL14600382 | 0.87 | HTT (0.66) | ACHEALDH1A1HPGDKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL9785687 | 0.86 | ACHE (0.62) | ACHEALDH1A1EPHX1L3MBTL3L3MBTL1 | |
| SCHEMBL14003456 | 0.85 | KMT2A (0.65) | ALDH1A1L3MBTL3L3MBTL1HPGDKMT2A | |
| SCHEMBL19106730 | 0.85 | RECQL (0.54) | ACHEALDH1A1L3MBTL3KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11795159-B2 | Compounds for the treatment of SARS | PURDUE RESEARCH FOUNDATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230183222-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183222-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-15 | — | — | US | disclosed |
| US-20220411401-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | PURDUE RESEARCH FOUNDATION | 2022-12-29 | — | — | US | disclosed |
| US-20210179595-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2021-06-17 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-7501406-B2 | Fluoro substituted 2-oxo-azepan derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7449485-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449485-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7417129-B2 | Combinatorial libraries of monosaccharides | ALCHEMIA PTY LTD (AU) | 2008-08-26 | — | — | US | disclosed |
| US-7417129-B2 | Combinatorial libraries of monosaccharides | ALCHEMIA PTY LTD (AU) | 2008-08-26 | — | — | US | disclosed |
| US-7358251-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070037789-A1 | 4-chloro-N-((R)-5,5-difluoro-2-oxo-azepan-3-yl)-N-[2-fluoro-4-(2H-[1,2,4]triazol-3-yl)-benzyl]-benzenesulfonamide; gamma -secretase inhibitor; neurodegenerative diseases; Alzheimer's disease; anticarcinogenic agent; cervical carcinomas and breast carcinomas and malignancies of the hematotic system | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | ACHE 210/4885ALDH1A1 684/4885EPHX1 974/4885 |
| US-20210179595-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | ACHE 282/4885ALDH1A1 250/4885EPHX1 2434/4885 |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | ACHE 3442/4885ALDH1A1 3835/4885EPHX1 2677/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | ACHE 4575/4885ALDH1A1 982/4885EPHX1 3913/4885 |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | ACHE 3575/4885ALDH1A1 3363/4885EPHX1 4497/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ACHE 210/4885ALDH1A1 684/4885EPHX1 974/4885 |
| US-11795159-B2 | Compounds for the treatment of SARS | ACE2, ACE, SARS1 | ACHE 286/4885ALDH1A1 3093/4885EPHX1 2271/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ACHE 210/4885ALDH1A1 684/4885EPHX1 974/4885 |
| US-20230183222-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | ACHE 282/4885ALDH1A1 250/4885EPHX1 2434/4885 |
| US-20070037789-A1 | 4-chloro-N-((R)-5,5-difluoro-2-oxo-azepan-3-yl)-N-[2-fluoro-4-(2H-[1,2,4]triazol-3-yl)-benzyl]-benzenesulfonamide; gamma -secretase inhibitor; neurodegenerative diseases; Alzheimer's disease; anticarcinogenic agent; cervical carcinomas and breast carcinomas and malignancies of the hematotic system | BACE1, BACE2, BRCA1 | ACHE 25/4885ALDH1A1 630/4885EPHX1 383/4885 |
| US-20220411401-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | ACE2, ACE, SARS1 | ACHE 286/4885ALDH1A1 3093/4885EPHX1 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.